JPMorgan Chase & Co. Cuts Alignment Healthcare (NASDAQ:ALHC) Price Target to $22.00

Alignment Healthcare (NASDAQ:ALHC) had its price target cut by JPMorgan Chase & Co. from $26.00 to $22.00 in a research note published on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

Other analysts have also issued research reports about the stock. Weiss Ratings raised shares of Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, May 7th. Barclays reduced their price target on shares of Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 26th. KeyCorp reaffirmed an “overweight” rating on shares of Alignment Healthcare in a report on Wednesday, June 10th. Raymond James Financial downgraded Alignment Healthcare from a “strong-buy” rating to an “outperform” rating and lowered their price objective for the stock from $22.00 to $19.00 in a research report on Monday. Finally, UBS Group reissued a “neutral” rating on shares of Alignment Healthcare in a research note on Wednesday, July 8th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.60.

Alignment Healthcare Stock Down 2.2%

Shares of NASDAQ ALHC opened at $13.38 on Tuesday. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. The company has a market cap of $2.78 billion, a P/E ratio of 70.42, a P/E/G ratio of 1.96 and a beta of 1.10. Alignment Healthcare has a 52 week low of $13.05 and a 52 week high of $25.12. The business has a 50-day simple moving average of $19.52 and a two-hundred day simple moving average of $19.52.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.04. Alignment Healthcare had a return on equity of 20.02% and a net margin of 0.89%.The firm had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same period in the prior year, the business posted $0.07 earnings per share. The company’s revenue was up 31.6% on a year-over-year basis. Research analysts anticipate that Alignment Healthcare will post 0.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alignment Healthcare news, insider Mark D. Kent acquired 14,848 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was purchased at an average cost of $13.31 per share, for a total transaction of $197,626.88. Following the acquisition, the insider owned 14,848 shares in the company, valued at $197,626.88. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Hyong Kim sold 35,951 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $19.86, for a total transaction of $713,986.86. Following the completion of the sale, the insider directly owned 331,750 shares of the company’s stock, valued at $6,588,555. This trade represents a 9.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,039,951 shares of company stock valued at $19,976,967 over the last 90 days. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Alignment Healthcare

Several hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP boosted its position in Alignment Healthcare by 8.9% during the 4th quarter. Allworth Financial LP now owns 6,917 shares of the company’s stock valued at $137,000 after acquiring an additional 566 shares in the last quarter. State of Alaska Department of Revenue raised its position in shares of Alignment Healthcare by 6.0% in the 4th quarter. State of Alaska Department of Revenue now owns 11,296 shares of the company’s stock worth $223,000 after acquiring an additional 636 shares in the last quarter. Integrated Wealth Concepts LLC lifted its stake in shares of Alignment Healthcare by 6.3% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock valued at $196,000 after purchasing an additional 665 shares during the period. Parallel Advisors LLC boosted its position in shares of Alignment Healthcare by 87.7% during the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after purchasing an additional 773 shares in the last quarter. Finally, Tidal Investments LLC grew its stake in Alignment Healthcare by 4.9% in the second quarter. Tidal Investments LLC now owns 18,094 shares of the company’s stock worth $253,000 after purchasing an additional 852 shares during the period. 86.19% of the stock is owned by institutional investors.

Key Headlines Impacting Alignment Healthcare

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Alignment Healthcare continues to post strong operating growth. Its 2026 outlook was reportedly raised alongside membership and revenue growth of more than 31%, although the company’s premium valuation and potential second-half risks may limit investor enthusiasm. Zacks analysis of Alignment Healthcare valuation and growth
• Neutral Sentiment: The company’s latest reported quarter exceeded consensus expectations for earnings and revenue, but investors appear more focused on forward guidance and execution risks than on the historical results.
• Negative Sentiment: Hagens Berman said it expanded an investor investigation following disappointing second-quarter 2026 financial guidance and whistleblower allegations concerning Alignment Healthcare’s financial practices. The allegations have not been proven, but they increase legal, reputational and disclosure risks. Hagens Berman Alignment Healthcare investor alert
• Negative Sentiment: Kaplan Fox, Lowey Dannenberg and other law firms announced or reiterated investigations into potential federal securities-law violations, encouraging investors who suffered losses to contact them. The repeated announcements are adding to selling pressure and uncertainty around the company’s financial disclosures. Lowey Dannenberg Alignment Healthcare investigation Kaplan Fox Alignment Healthcare investigation
• Negative Sentiment: Raymond James reportedly downgraded Alignment Healthcare to Outperform, contributing to the negative sentiment. The move suggests a less favorable risk-reward view despite the company’s rapid growth. Raymond James analyst action on Alignment Healthcare

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.